Cancer-associated thrombosis: what is new?

IF 2.8 4区医学 Q2 ONCOLOGY Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-16 DOI:10.1097/CCO.0000000000001125

Isabelle Mahé, Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac

{"title":"Cancer-associated thrombosis: what is new?","authors":"Isabelle Mahé, Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac","doi":"10.1097/CCO.0000000000001125","DOIUrl":null,"url":null,"abstract":"Purpose of review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.Recent findings: Consequently, news issues emerge for clinical practice: anticoagulation therapy personalization is required to optimize the benefit ratio, involving patient characteristics and cancer characteristics. During follow-up, prediction score are designed and investigated to help identify and discriminate patients at risk of venous thromboembolism recurrences and major bleedings. Considering the improved prognosis of patients with cancer and cancer-associated thrombosis, the question of extended treatment arises, representing a major unmet need to date. Finally, new strategies, in particular anti-XI agents that appear attractive options, are currently being evaluated in the treatment of thrombosis associated with cancer.Summary: The improved prognosis of patients with cancer-associated thrombosis is accompanied by new therapeutic strategies to improve the benefit-risk ratio of anticoagulant treatment in these fragile patients, at risk of both venous thromboembolic recurrence and haemorrhagic complication.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"150-157"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001125","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.

Recent findings: Consequently, news issues emerge for clinical practice: anticoagulation therapy personalization is required to optimize the benefit ratio, involving patient characteristics and cancer characteristics. During follow-up, prediction score are designed and investigated to help identify and discriminate patients at risk of venous thromboembolism recurrences and major bleedings. Considering the improved prognosis of patients with cancer and cancer-associated thrombosis, the question of extended treatment arises, representing a major unmet need to date. Finally, new strategies, in particular anti-XI agents that appear attractive options, are currently being evaluated in the treatment of thrombosis associated with cancer.

Summary: The improved prognosis of patients with cancer-associated thrombosis is accompanied by new therapeutic strategies to improve the benefit-risk ratio of anticoagulant treatment in these fragile patients, at risk of both venous thromboembolic recurrence and haemorrhagic complication.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.

期刊最新文献

Cancer-associated thrombosis: what is new? Chemotherapy-induced nausea and vomiting: can we do better? Emerging toxicities in oncology. How to monitor the side effects of treatments in cancer patients. From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma.